Anidulafungin versus Fluconazole for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis. METHODS: Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole. All patients could receive oral fluconazole after 10 days of intravenous therapy. The primary efficacy analysis assessed the global response (clinical and microbiologic) at the end of intravenous therapy in patients who had a positive baseline culture. Efficacy was also assessed at other time points. RESULTS: Eighty-nine percent of the 245 patients in the primary analysis had candidemia only. Candida albicans was isolated in 62% of the 245 patients. In vitro fluconazole resistance was infrequent. Most of the patients (97%) did not have neutropenia. At the end of intravenous therapy, treatment was successful in 75.6% of patients treated with anidulafungin, as compared with 60.2% of those treated with fluconazole (difference, 15.4 percentage points; 95% confidence interval [CI], 3.9 to 27.0). The results were similar for other efficacy end points. The statistical analyses failed to show a "center effect"; when data from the site enrolling the largest number of patients were removed, success rates at the end of intravenous therapy were 73.2% in the anidulafungin group and 61.1% in the fluconazole group (difference, 12.1 percentage points; 95% CI, -1.1 to 25.3). The frequency and types of adverse events were similar in the two groups. The rate of death from all causes was 31% in the fluconazole group and 23% in the anidulafungin group (P=0.13). CONCLUSIONS: Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasive candidiasis. (ClinicalTrials.gov number, NCT00056368 [ClinicalTrials.gov]).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
In the citing paper
“A randomized controlled trial, more robust for examining effects of treatment, found superior outcomes for patients who received an echinocandin as primary treatment for invasive candidiasis [12].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [12]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citationSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citationTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Self-citationRex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Self-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Research works printed but not linked: 4
- Graybill JR, 2001, Curr Opin Investig Drugs, 2, 468
- Espinel-Ingroff A, 2003, Rev Iberoam Micol, 20, 121
- Park S, Paderu P, Perlin DS. Amino acid polymorphisms in Fks1 from C. parapsilosis, C. metapsilosis and C. orthopsilosis strains account for intrinsic reduced susceptibility to echinocandin drugs. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006.
- 10.1002/(SICI)1097-0258(19960830)15:16<1729::AID-SIM334>3.0.CO;2-M · doi:10.1002/(sici)1097-0258(19960830)15:16<1729::aid-sim334>3.0.co;2-m
Cited by
Items 301–400 of 892
Puig‐Asensio, M., Fernández‐Ruiz, M., Aguado, J. M., Merino, P., Lora, D., Guinea, J., Martín‐Dávila, P., Cuenca‐Estrella, M., & Almirante, B. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00195-16 · Cited by 28
“To date, only one randomized clinical trial has compared fluconazole at a standard dose of 400 mg/day and anidulafungin for invasive candidiasis (30).”
BackgroundClinical Pharmacology of Anti-Infective Drugs
Wade, K. C., & Benjamin, D. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6400-8.00037-7 · Cited by 32
Candida parapsilosis Sensu Stricto Antifungal Resistance Mechanisms and Associated Epidemiology
Franconi, I., Rizzato, C., Poma, N. V., Tavanti, A., & Lupetti, A. (2023) · Journal of Fungi · doi:10.3390/jof9080798 · Cited by 29
“Their spectrum is broader tha fluconazole and rates of fungal eradication were report d to be higher than fluconazol [118]; therefor , echinocandins are the recomme ed treatment in case of candidemia and invasive fungal infections due to Candida spp.”
BackgroundImmunotherapy: a potential adjunctive treatment for fungal infection
Kullberg, B. J., van de Veerdonk, F. L., & Netea, M. G. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000105 · Cited by 30
“However, the crude mortality rate among patients with candidaemia is still around 25% [6], and up to 50% in patients presenting with septic shock [7].”
BackgroundAnidulafungin in the treatment of invasive fungal infections
Gumbo, T. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s882 · Cited by 27
“However, in the recently completed invasive candidiasis trial, 15 of 127 patients receiving anidulafungin reported an adverse event resulting in discontinuation of the drug (Reboli et al 2007).”
Newer antifungal agents for invasive fungal infections in patients with haematological malignancy
Rogers, T. R., & Frost, S. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07412.x · Cited by 29
“A randomised double blind multi-centre study compared anidulafungin with fluconazole for treatment of candidaemia (excluding C. krusei because fluconazole was the comparator) or selected other invasive candidiasis presentations (Reboli et al, 2007).”
ResultThe effects of antifungal stewardship programs at a tertiary-care teaching hospital in Japan
Kawaguchi, H., Yamada, K., Imoto, W., Yamairi, K., Shibata, W., Namikawa, H., Yoshii, N., Nakaie, K., Okada, Y., Fujita, A., et al. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.01.015 · Cited by 29
“[13] Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al.”
BackgroundCurrent and promising pharmacotherapeutic options for candidiasis
Scorzoni, L., Fuchs, B. B., Junqueira, J. C., & Mylonakis, E. E. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1873951 · Cited by 36
Li, Q., Jiang, Z., Ren, S., Guo, H., Song, Z., Chen, S., Gao, X., Meng, F., Zhu, J., Liu, L., et al. (2022) · Advanced Science · doi:10.1002/advs.202203088 · Cited by 25
Grossi, P., Gasperina, D. D., Barchiesi, F., Biancofiore, G., Carafiello, G., GASPERI, A. D., Sganga, G., Menichetti, F., Montagna, M. T., Pea, F., et al. (2011) · Transplantation Proceedings · doi:10.1016/j.transproceed.2011.06.020 · Cited by 26
Management ofCandidainfections in the adult intensive care unit
Cruciani, M., & Serpelloni, G. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.2.175 · Cited by 33
Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital
Battistolo, J., Glampedakis, E., Damonti, L., Poissy, J., Grandbastien, B., Kalbermatter, L., Pagani, J., Eggimann, P., Bochud, P., Calandra, T., et al. (2021) · Mycoses · doi:10.1111/myc.13376 · Cited by 29
DectiSomes: Glycan Targeting of Liposomal Drugs Improves the Treatment of Disseminated Candidiasis
Ambati, S., Pham, T., Lewis, Z., Lin, X., & Meagher, R. B. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01467-21 · Cited by 26
Xu, S.-X., Shen, J., Tang, X. F., & Feng, B. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2012.07.149 · Cited by 24
Reboli, A. C., Rotstein, C., Kett, D. H., Maschio, M., Cartier, S., Chambers, R. B., & Tarallo, M. (2011) · PharmacoEconomics · doi:10.2165/11584810-000000000-00000 · Cited by 26
Self-citationÉpidémiologie des candidémies : étude observationnelle prospective d’un an dans l’Ouest de la France
Talarmin, J. P., Boutoille, D., Tattevin, P., Dargère, S., Weinbreck, P., Ansart, S., Chennebault, J. M., Hutin, P., Leautez-Nainville, S., Gay‐Andrieu, F., et al. (2009) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2009.02.008 · Cited by 30
The Use of Antifungal Therapy in Neonatal Intensive Care
Testoni, D., Smith, P. B., & Benjamin, D. K. (2012) · Clinics in Perinatology · doi:10.1016/j.clp.2011.12.008 · Cited by 24
Ou, H., Lee, T., Chen, Y., & Charbonneau, C. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2573-8 · Cited by 26
“The life expectancy for the survived cases was estimated in the following steps: (a) assume an average age of patients with IC were approximately 58 years old [8], (b) assume the remaining life expectancy of a 58-year-old person (without IC) is 25.”
BackgroundMethodResultInfluentialVázquez, J. A., & Sobel, J. D. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_11 · Cited by 37
Combination antifungals: an update
Segal, B. H., & Steinbach, W. J. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.5.883 · Cited by 27
Darouiche, R. O. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.02.013 · Cited by 23
Real-life epidemiology and current outcomes of hospitalized adults with invasive fungal infections
Monzó, P., Chumbita, M., Lopera, C., Aiello, T. F., Peyrony, O., Bodro, M., Herrera, S., Sempere, A., Fernández-Pittol, M., Cuesta, G., et al. (2023) · Medical Mycology · doi:10.1093/mmy/myad021 · Cited by 27
Falcone, M., Tiseo, G., Gutiérrez‐Gutiérrez, B., Raponi, G., Carfagna, P., Rosin, C., Luzzati, R., Rose, D. D., Andreoni, M., Farcomeni, A., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz251 · Cited by 24
Identification of Inhibitors of Fungal Fatty Acid Biosynthesis
DeJarnette, C. A., Meyer, C. J., Jenner, A. R., Butts, A., Peters, T. L., Cheramie, M. N., Phelps, G. A., Vita, N. A., Loudon, V. C., Lee, R. E., Jr., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00404 · Cited by 25
DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs
Meagher, R. B., Lewis, Z., Ambati, S., & Lin, X. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114776 · Cited by 27
Rieger, C. T., Cornely, O. A., Hoppe‐Tichy, T., Kiehl, M. G., Knoth, H., Thalheimer, M., Schuler, U. S., Ullmann, A. J., EHLKEN, B., & Ostermann, H. (2012) · Mycoses · doi:10.1111/j.1439-0507.2012.02193.x · Cited by 23
Treatment of critically ill patients with candidemia
Mensa, J., Pitart, C., & Marco, F. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70007-4 · Cited by 26
“Candins have been compared to amphotericin B deoxycholate (caspofungin) [17], liposomal amphotericin B (micafungin) [18], and fluconazole (anidulafungin) [19].”
ResultWalraven, C. J., Bernardo, S. M., Wiederhold, N. P., & Lee, S. A. (2014) · Medical Mycology · doi:10.1093/mmy/myt007 · Cited by 23
“In randomized clinical trials, the echinocandins have demonstrated excellent efficacy against Candida albicans and non-Candida albicans Candida species involved in invasive and disseminated infections [1–4].”
Shorr, A. F., Wu, C., & Kothari, S. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq446 · Cited by 24
Initial antifungal strategy does not correlate with mortality in patients with candidemia
Murri, R., Scoppettuolo, G., Ventura, G., Fabbiani, M., Giovannenze, F., Taccari, F., Milozzi, E., Posteraro, B., Sanguinetti, M., Cauda, R., et al. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2527-2 · Cited by 24
“It is important to note, however, that no difference in mortality was found in the single randomized clinical trial that compared an echinocandin (anidulafungin) to fluconazole [18].”
Rampini, S. K., Zbinden, A., Speck, R. F., & Bloemberg, G. V. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0752-1 · Cited by 25
“This may be explained by the in general weak potency of antifungal drugs [33–35], empirical treatment not covering the fungal species eventually identified (12/31), specimens obtained for microbiological workup shortly after start of anti-fungal treatment (10/31 within 3 days), or poor drug penetration into surgical s…”
BackgroundRiddell, J., & Kauffman, C. A. (2008) · Cancer · doi:10.1002/cncr.23465 · Cited by 23
“The echinocandins are considered equivalent to amphotericin B and fluconazole for candidemia.(14,15) In institutions that have lower rates of infection with C.”
BackgroundInvasive fungal infections in pediatric patients: a review focusing on antifungal therapy
Lass‐Flörl, C. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.128 · Cited by 26
Sganga, G., Wang, M., Capparella, M. R., Tawadrous, M., Yan, J. L., Aram, J. A., & Montravers, P. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03617-9 · Cited by 25
Domingos, E. L., Vilhena, R. D. O., dos Santos, J. M. M. F., Fachi, M. M., Böger, B., Adam, L. M., Tonin, F. S., & Pontarolo, R. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106614 · Cited by 23
Vena, A., Bovis, F., Tutino, S., Barbone, A. S., Mezzogori, L., Ponzano, M., Taramasso, L., Baldi, F., Dettori, S., Labate, L., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac656 · Cited by 26
Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients
Glöckner, A., & Karthaus, M. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01885.x · Cited by 25
Livermore, J., Felton, T., Abbott, J., Sharp, J., Goodwin, J., Gregson, L., Warn, P. A., Howard, S. J., & Hope, W. W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01387-12 · Cited by 24
“treatment of invasive candidiasis and candidemia (12).”
Kontoyiannis, D. P., Bassetti, M., Nucci, M., Capparella, M. R., Yan, J. L., Aram, J. A., & Hogan, P. A. (2017) · Mycoses · doi:10.1111/myc.12641 · Cited by 22
Jaffal, K., Poissy, J., Rouzé, A., Préau, S., Sendid, B., Cornu, M., & Nseir, S. (2018) · Annals of Intensive Care · doi:10.1186/s13613-018-0392-8 · Cited by 25
Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R., & Patterson, T. F. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03712.x · Cited by 22
“Anidulafungin has been shown to be non-inferior to fluconazole for invasive candidiasis in a prospective, randomized clinical trial [1].”
BackgroundPresent situation in the treatment of invasive fungal infection
Pauw, B. E. D., & Picazo, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70020-7 · Cited by 25
“Anidulafungin has been approved for candidaemia and other forms of infection by Candida (intra-abdominal abscesses and peritonitis) and for oesophageal candidiasis [18].”
BackgroundPharmacokinetic evaluation of fluconazole in critically ill patients
Sinnollareddy, M., Peake, S., Roberts, M. S., Playford, E. G., Lipman, J., & Roberts, J. A. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.615309 · Cited by 22
“In contrast, fluconazole may be less effective than the echinocandin, anidulafungin (100 mg/day) and may have an inferior safety profile [71].”
BackgroundCandidaemia in the non-neutropenic patient: A critique of the guidelines
Deshpande, A., Gaur, S., & Bal, A. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.06.005 · Cited by 26
Treatment of invasive candidiasis with echinocandins
Glöckner, A., Steinbach, A., Vehreschild, J. J., & Cornely, O. A. (2009) · Mycoses · doi:10.1111/j.1439-0507.2008.01645.x · Cited by 23
Anidulafungin for the treatment of invasive candidiasis
Mayr, A., Aigner, M., & Lass‐Flörl, C. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03448.x · Cited by 25
McCort, M., & Tsai, H. (2023) · Mycopathologia · doi:10.1007/s11046-023-00754-w · Cited by 26
Echinocandins--new antifungal agents.
Stan, C. D., Tuchiluş, C., & Stan, C. I. (2014) · The Medical-Surgical Journal · Cited by 26
Espinel‐Ingroff, A., Cantón, R., Pemán, J., & Martín‐Mazuelos, E. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01324-09 · Cited by 22
Nucci, M., Colombo, A. L., Petti, M., Magana, M., Abreu, P., Schlamm, H. T., & Sanchez, S. P. (2014) · Mycoses · doi:10.1111/myc.12094 · Cited by 21
Current Role of Echinocandins in the Management of Invasive Aspergillosis
Mikulska, M., & Viscoli, C. (2011) · Current Infectious Disease Reports · doi:10.1007/s11908-011-0216-6 · Cited by 25
Pharmacokinetics of antifungal agents in children
Watt, K., Benjamin, D. K., & Cohen‐Wolkowiez, M. (2011) · Early Human Development · doi:10.1016/j.earlhumdev.2011.01.014 · Cited by 25
“Amphotericin B deoxycholate has often been the standard against which these new therapies are measured [4–9].”
BackgroundAnidulafungin Pharmacokinetics in Ascites Fluid and Pleural Effusion of Critically Ill Patients
Welte, R., Eller, P., Lorenz, I. H., Joannidis, M., & Bellmann, R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02326-17 · Cited by 23
New options for treatment of candidaemia in critically ill patients
Ruhnke, M., Härtwig, K., & Kofla, G. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01981.x · Cited by 25
Systemic Review of Published Literature on Candida Infection Following Total Hip Arthroplasty
Kim, S., Huh, J., Odrobina, R., & Kim, J. H. (2014) · Mycopathologia · doi:10.1007/s11046-014-9852-3 · Cited by 21
“with favorable safety profile [30] and possible superiority over fluconazole for candidemia [43], primary use of echinocandin needs to be considered in cases of Candida spp.”
BackgroundWu, J., Xie, S., Zhang, G., Zhan, J., Xie, W., Yu, R., Xue, B., Cen, Y., Chai, J., Chen, H., et al. (2014) · Burns & Trauma · doi:10.4103/2321-3868.130182 · Cited by 24
“Antifungal agents include mainly polyenes (amphotericin B), azoles (fluconazol, itraconazole, voriconazol) and candins (caspofungin and micafungin).([56-59]) For prophylaxis purpose, azole or candin agents are always used but not polyenes.”
BackgroundWiederhold, N. P., Najvar, L. K., Matsumoto, S., Bocanegra, R. A., Herrera, M., Wickes, B. L., Kirkpatrick, W. R., & Patterson, T. F. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04857-14 · Cited by 21
Gold, J. A. W., Seagle, E. E., Nadle, J., Barter, D. M., Czaja, C. A., Johnston, H., Farley, M. M., Thomas, S., Harrison, L. H., Fischer, J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab512 · Cited by 20
“echinocandin as primary treatment for invasive candidiasis [12].”
BackgroundAldejohann, A. M., Menner, C., Thielemann, N., Martin, R., Walther, G., & Kurzai, O. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01324-23 · Cited by 23
Rubio-Rodríguez, D., Grau, S., Pozo, J. C., Romá, E., Salavert, M., Barrueta, J. A., Peral, C., Rodriguez, I., & Rubio‐Terres, C. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s91587 · Cited by 28
“8,25–28 A total of 1,000 Monte Carlo simulations were performed on a hypothetical cohort of 1,000 patients for the three variables (overall success rate, hepatic adverse effects, and renal toxicity rate for each treatment), which were adjusted for β -statistical distributions.”
Echinocandin-Resistant Candida: Molecular Methods and Phenotypes
Perlin, D. S. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0054-x · Cited by 22
Scott, B. L., Hornik, C. D., & Zimmerman, K. O. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1773793 · Cited by 26
Borgonovo, F., Quici, M., Gidaro, A., Giustivi, D., Cattaneo, D., Gervasoni, C., Calloni, M. V., Martini, E., Cava, L. L., Antinori, S., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12081338 · Cited by 31
Treatment of Invasive Candidiasis in Immunocompromised Pediatric Patients
Fisher, B. T., & Zaoutis, T. E. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00003 · Cited by 22
Mootsikapun, P., Hsueh, P.-R., Talwar, D., Co, V. M., Rajadhyaksha, V., & Ong, M.-L. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-219 · Cited by 20
“%) was Table 4 Clinical, microbiological, and global response rates at various pre-defined efficacy timepoints throughout the study in the MITT population MITT population Timepoint Clinical response, % [n/N] (95% CI) Microbiological response, % [n/N] (95% CI) Global response, % [n/N] (95% CI) End of intravenous treatm…”
BackgroundResultInfluentialThe Diagnostic and Therapeutic Approach to Fungal Infections in Critical Care Settings
Zaragoza, R., & Pemán, J. (2008) · Cited by 21
Martín-Gutiérrez, G., Peñalva, G., de Pipaón, M. R.-P., Aguilar, M., Gil-Navarro, M. V., Perez-Blanco, J.-L., Pérez-Moreno, M. A., Amaya‐Villar, R., Ferrándiz‐Millón, C., Gascón, M. L., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.01.002 · Cited by 22
Efficacy of caspofungin in invasive candidiasis and candidemia – de‐escalation strategy
Lichtenstern, C., Nguyen, T. H., Schemmer, P., Hoppe‐Tichy, T., & Weigand, M. A. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01527.x · Cited by 20
Elalouf, A., Elalouf, H., & Rosenfeld, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292625 · Cited by 24
Infecciones asociadas a dispositivos intravasculares utilizados para la terapia de infusión
Fortün, J. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13116754 · Cited by 31
“En cepas resistentes a azoles el tratamiento debe realizar-se con una equinocandina o anfotericina B 39,40 .”
A scoring model of factors associated with Candida glabrata candidemia among critically ill patients
Tapia-Zegarra, G. G., Razonable, R. R., Eckel‐Passow, J. E., Lahr, B. D., Afessa, B., Keegan, M. T., Catania, J., & Baddour, L. M. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02069.x · Cited by 22
Najvar, L. K., Bocanegra, R. A., Wiederhold, N. P., Lambros, C., Najarian, N., Patterson, T. F., & Graybill, J. R. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01994.x · Cited by 20
“70% of patients [2–4].”
Glöckner, A., & Cornely, O. A. (2012) · Mycoses · doi:10.1111/j.1439-0507.2012.02208.x · Cited by 21
Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis
Dupont, H., Massias, L., Jung, B., Ammenouche, N., & Montravers, P. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw568 · Cited by 19
Tiraboschi, I. N., Pozzi, N. C., Farías, L., García, S., & Fernández, N. (2017) · Revista chilena de infectología · doi:10.4067/s0716-10182017000500431 · Cited by 31
From the Clinical Mycology Laboratory: New Species and Changes in Fungal Taxonomy and Nomenclature
Wiederhold, N. P., & Gibas, C. F. C. (2018) · Journal of Fungi · doi:10.3390/jof4040138 · Cited by 20
Echinocandins: a wealth of choice – how clinically different are they?
Zaas, A. K. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328307c79c · Cited by 24
Zaragoza, R., Ferrer, R., Maseda, E., Llinares, P., & Rodríguez, A. H. (2014) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2014.06.001 · Cited by 17
Hissong, E. M., Schechter, S. A., Mowers, J. C., Yantiss, R. K., Slavík, T., Cheng, J., & Lamps, L. W. (2020) · Histopathology · doi:10.1111/his.14063 · Cited by 18
Auzinger, G. M., Playford, E. G., Graham, C. N., Knox, H. N., Weinstein, D. L., Kantecki, M., Schlamm, H. T., & Charbonneau, C. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1143-1 · Cited by 20
“the 96 average age of patients in the study by Reboli and colleagues [15]) in the United King dom.”
BackgroundMethodInfluentialMiyazaki, T., & Kohno, S. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1058157 · Cited by 20
“Detailed evidence on treatment periods is lacking, but because recurrence rates were low with the criteria in the large RCTs [68,73,75,76] that have been performed to date (2 weeks after symptoms caused by candidemia improve, and negative blood culture result is confirmed), the IDSA, ESCMID and both Japanese guideline…”
BackgroundInfluentialDudiuk, C., Gamarra, S. P., Jiménez‐Ortigosa, C., Leonardelli, F., Macedo, D., Perlin, D. S., & García‐Effrón, G. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00398-15 · Cited by 23
Neonatal Peritoneal Candidiasis Successfully Treated with Anidulafungin Add-On Therapy
Varisco, B. M., Benner, K., & Prabhakaran, P. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m350 · Cited by 18
Nemer, S., Imtiaz, T., Varikkara, M., Collier, A., & Bal, A. M. (2019) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2019.1606436 · Cited by 21
“albicans, even though an overwhelming majority of the species is known to be susceptible to the latter agent [21].”
BackgroundBretagne, S., Desnos‐Ollivier, M., Sitbon, K., Lortholary, O., Che, D., Dromer, F., & YEASTS, P. O. T. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.641965 · Cited by 19
“One of the recommendations is the strong incentive for using echinocandin instead of fluconazole as first-line therapy based on analysis of randomized trials (11, 12).”
BackgroundAnidulafungin: when and how? The clinician’s view
George, J. M., & Reboli, A. C. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02052.x · Cited by 18
Self-citationManagement of Acute Respiratory Failure in Patients With Hematological Malignancy
Vadde, R., & Pastores, S. M. (2015) · Journal of Intensive Care Medicine · doi:10.1177/0885066615601046 · Cited by 18
“Other fungal infections that are frequently seen include invasive candidiasis and mucormycosis.(49) Treatment and duration of antimicrobial therapy for fungal pneumonias are shown in Table 2.”
BackgroundInfections in the Cancer Patient
Marchetti, O., Tissot, F., & Calandra, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00079-4 · Cited by 22
Rae, N., Kenny, C. C., & Muldoon, E. G. (2018) · Mycoses · doi:10.1111/myc.12874 · Cited by 19
“Echinocandins have demonstrated superiority in the management of candidaemia, in particular in critically ill patients, and as such are recommended as first line therapy [41, 42].”
BackgroundDignani, M. C., Solomkin, J. S., & Anaissie, E. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00008-6 · Cited by 34
Evolving strategies in the management of aspergillosis
Magill, S. S., Chiller, T. M., & Warnock, D. W. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.2.193 · Cited by 19
Jacobs, S. E., & Chaturvedi, V. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae646 · Cited by 17
“However, as compared to rare IFDs, randomized trials of antifungal combinations for treatment of candidemia are more feasible, as evidenced by prior well-done RCTs comparing single drugs [44, 45].”
Choice and duration of antifungal prophylaxis and treatment in high-risk haematology patients
Coussement, J., Lindsay, J., Teh, B. W., & Slavin, M. A. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000737 · Cited by 18
Fisher, B. T., Zaoutis, T. E., Xiao, R., Wattier, R. L., Castagnola, E., Pana, Z. D., Fullenkamp, A., Boge, C. L. K., Ross, R. K., Yildirim, I. B., et al. (2021) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piab024 · Cited by 18
Pfaller, M. A., Castanheira, M., Lockhart, S. R., & Jones, R. N. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0091-0 · Cited by 21
“glabrata [44–49].”
Candidemia y candidiasis invasora en el adulto. Formas clínicas y tratamiento
Cervera, C. (2012) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2012.02.003 · Cited by 48
Noninferiority trial designs for odds ratios and risk differences
Hilton, J. F. (2010) · Statistics in Medicine · doi:10.1002/sim.3846 · Cited by 19
Butts, A., Reitler, P., Nishimoto, A. T., DeJarnette, C. A., Estredge, L. R., Peters, T. L., Veve, M. P., Rogers, P. D., & Palmer, G. E. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00054-19 · Cited by 18
Antifungal Clinical Trials and Guidelines: What We Know and Do Not Know
Pappas, P. G. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019745 · Cited by 18
“…end points, with a focus on clearance of candidemia from the bloodstream and/or resolution of all symptoms and signs related to invasive candidiasis at the end of therapy (Mora-Duarte et al. 2002; Kullberg et al. 2005; Kuse et al. 2007; Pappas et al. 2007; Reboli et al. 2007; Vazquez et al. 2014).”
BackgroundResultSelf-citationGumbo, T. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ715 · Cited by 16
“classes of antifungal agents for the treatment of candidemia and other forms of deeply invasive candidiasis [8, 9].”
Background
Metadata
- Authors
- Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., Krause, D. S., & Walsh, T. J.
- Affiliations
- Cooper University Hospital (US)
- Hamilton Health Sciences (CA)
- University of Alabama at Birmingham (US)
- University of Mississippi (US)
- University of Miami (US)
- University Health Network (CA)
- University of Rochester (US)
- Vifor Pharma (Germany) (DE)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2472-2482
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126319933
- Cited by
- 894
- References
- 27
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 21 · 2023: 33 · 2022: 23 · 2021: 37 · 2020: 47 · 2019: 34 · 2018: 40 · 2017: 29 · 2016: 34 · 2015: 44 · 2014: 46 · 2013: 55 · 2012: 52
- FWCI
- 58.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Eli Lilly and Company
- Pfizer
- Viropharma
- Astellas Pharma
- Basilea Pharmaceutica
- Duke Clinical Research Institute
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- anidulafungin, fluconazole, invasive candidiasis, echinocandins, candidemia, Candida albicans, non-inferiority, antifungal therapy, mortality, fluconazole resistance
- MeSH terms
- Anidulafungin, Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Candidiasis, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Peptides, Cyclic, Fluconazole, Fungemia, Treatment Outcome, Kaplan-Meier Estimate, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.